Albany, NY -- (SBWIRE) -- 06/01/2020 -- Osteoporosis Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Osteoporosis Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total diagnosed prevalent population of osteoporosis in the seven major markets was found to be 28,097,783 cases in 2017.
2. The total diagnosed prevalent population of Osteoporosis in the United States was found to be 6,380,754 cases in 2017.
3. Osteoporosis is more in females as compared to males.

Key benefits of the report
1. Osteoporosis market report covers a descriptive overview and comprehensive insight of the Osteoporosis epidemiology and Osteoporosis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Osteoporosis market report provides insights into the current and emerging therapies.
3. Osteoporosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Osteoporosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Osteoporosis market.

Request for sample pages

"Osteoporosis market size in the seven major markets was 9,442.73 USD Million in 2017".

Osteoporosis treatment involves treating and preventing fractures and using medicines to strengthen the weak bones. For patients, who are at high risk, drug treatments are required to decrease the risk of broken bones due to osteoporosis effectively. Osteoporosis Treatments have been shown to lessen the risk of hip fracture by up to 40%, vertebral fractures by 30-70% and, with some medications, decrease the risk for non-vertebral fractures by 15-20%.

The treatment landscape of osteoporosis comprises majorly of pharmacological therapies, which is further characterized as anti-resorptive agents (i.e., bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab), anabolic agents (i.e., teriparatide and abaloparatide), and mixed agents (i.e., Romosozumab). Apart from the mentioned pharmacotherapies, there are several other anti-resorptive treatment options to treat osteoporosis, such as estrogen replacement and selective estrogen receptor modulators, which further comprises of raloxifene, lasofoxifene, and bazedoxifene. Also, few dietary supplements such as calcium and vitamin D also provide benefit to patients with osteoporosis.

The launch of the emerging therapies is expected to significantly impact the Osteoporosis treatment scenario in the upcoming years:-
Drugs covered
1. Alendronate
2. Zoledronic Acid
3. NaQuinate (Osteopura)
And many others

The key players in Osteoporosis market are:
1. Amgen
2. Haoma Medica
And many others

Table of contents
1. Key Insights
2. Osteoporosis Market Overview at a Glance
3. Disease Background and Overview: Osteoporosis
4. Recognized Establishments
4.1.1. United States
4.1.2. Europe
4.1.3. Japan
5. Osteoporosis Epidemiology and Patient Population
6. Country Wise- Osteoporosis Epidemiology
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
6.8. Japan
7. Osteoporosis Treatment
8. Endocrine Society: 2019
9. National Osteoporosis Guideline Group (NOGG): 2018
10. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: 2017
11. American College of Physicians (ACP): 2017
12. Unmet Needs
13. Osteoporosis Marketed Drugs
13.1. Marketed Drugs Key-cross Competition
13.2. Evenity (Romosozumab-aqqg): Amgen
13.3. Prolia (Denosumab): Amgen
13.4. Fablyn (Lasofoxifene): Pfizer
13.5. Duavee (conjugated estrogens/bazedoxifene): Pfizer
13.6. Tymlos (abaloparatide): Radius Health
13.7. Bijuva (estradiol and progesterone): Therapeutics MD
13.8. Boniva (ibandronate sodium): Roche
13.9. Reclast (zoledronic acid): Novartis Pharmaceuticals
13.10. Forteo/Forsteo (Teriparatide): Eli Lilly
13.11. Bonsity (PF708): Pfenex
14. Osteoporosis Emerging Drugs
14.1. Key Cross Competition
14.2. Alendronate/Zoledronic Acid: Amgen
14.3. NaQuinate (Osteopura): Haoma Medica
15. What Experts Say?
16. Osteoporosis: 7 Major Market Analysis
16.1. Key Findings
16.2. Market Size of Osteoporosis in the 7MM
17. The United States Market Outlook
17.1. United States
18. EU-5 Countries: Market Outlook
18.1. Germany
18.2. France
18.3. Italy
18.4. Spain
18.5. United Kingdom
19. Japan: Market Outlook
20. Case Reports
21. Market Drivers
22. Market Barriers
23. Appendix
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight